A Phase 1 interventional study of MET233 and Placebo in Obesity and Overweight, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.
Among the 64 studies in Obesity by Pfizer, this one is the 29th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 in phase 1, and was the 44th registered.
11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 14 · Phase 3 17
First in 2004; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 127 across the 62 interventional studies, 53,752 across the 2 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
8 of the studies in Obesity by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07725809PfizerA Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-01-13 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
Add all 8 to your calendar (.ics) → With an account.
Among the 64 studies in Obesity by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.
This study will be conducted in four parts:
This is a randomized, placebo-controlled, double-blind study designed to investigate the safety, tolerability, PK and pharmacodynamic (PD) of single and multiple ascending subcutaneous (SC) doses of MET233 in otherwise healthy adult participants with obesity or overweight (body mass index [BMI] 27.0 kg/m2 to 38.0 kg/m2, inclusive for Parts A-C and BMI in Part D 30- 45.0 kg/m2 (inclusive).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of MET233 at up to 5 dose levels
Biological: MET233
Participants will receive a single dose of placebo
Biological: Placebo
Participants will receive five weekly doses of MET233 at up to 4 dose levels
Biological: MET233
Participants will receive five weekly doses of placebo
Biological: Placebo
Participants will receive twelve weekly doses of MET233 at up to 4 dose levels, followed by a 13th potential monthly dose
Biological: MET233
Participants will receive twelve weekly doses of placebo, followed by a 13th potential monthly dose
Biological: Placebo
Participants will receive twelve weekly doses of MET233, followed by three monthly doses.
Biological: MET233
Participants will receive twelve weekly doses of placebo, followed by three monthly doses.
Biological: Placebo
For subcutaneous administration
Sterile 0.9% (w/v) saline for subcutaneous administration
Occurrence of Treatment Emergent Adverse Events
Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Area under the concentration versus time curve extrapolated to infinity (AUCinf)
Time frame: Part A (Baseline to Day 85)
Area under the concentration versus time curve during the dosing interval (AUCtau)
Time frame: Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Maximum observed concentration (Cmax)
Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Time to maximum observed concentration (Tmax)
Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Elimination half-life (t1/2)
Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Percent change from baseline in body weight at the protocol-specified weekly post-baseline measurements
Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2024 to primary completion in May 2026, 18 months.
Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 18 months is above that.
Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Apr 2026 → May 2026 and completion Apr 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.